Adicet Bio, Inc. Operating Income
Adicet Bio, Inc. (ACET) reported Operating Income of -$22.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Adicet Bio, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$22.30M.
- Adicet Bio, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$21.57M.
- Adicet Bio, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$31.89M.
- Adicet Bio, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$27.95M.
- Adicet Bio, Inc. operating income (loss) for fiscal 2025 was -$122.11M.
- Adicet Bio, Inc. operating income (loss) for fiscal 2024 was -$127.61M.
- Adicet Bio, Inc. operating income (loss) for fiscal 2023 was -$152.04M.
- Adicet Bio, Inc. operating income (loss) for fiscal 2022 was -$72.55M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$22.30M 10-Q · filed 2026-08-05 | -$43.87M 10-Q · filed 2026-08-05 | -$75.76M derived: sum of 3 quarters · filed 2026-08-05 | -$103.71M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$21.57M 10-Q · filed 2026-05-13 | -$53.46M derived: sum of 2 quarters · filed 2026-05-13 | -$81.41M derived: sum of 3 quarters · filed 2026-05-13 | -$113.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$31.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$59.84M derived: sum of 2 quarters · filed 2026-03-12 | -$92.23M derived: sum of 3 quarters · filed 2026-08-05 | -$122.11M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$27.95M 10-Q · filed 2025-11-05 | -$60.34M derived: sum of 2 quarters · filed 2026-08-05 | -$90.23M 10-Q · filed 2025-11-05 | -$120.97M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$32.39M 10-Q · filed 2026-08-05 | -$62.28M 10-Q · filed 2026-08-05 | -$93.02M derived: sum of 3 quarters · filed 2026-08-05 | -$126.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$29.89M 10-Q · filed 2026-05-13 | -$60.63M derived: sum of 2 quarters · filed 2026-05-13 | -$93.78M derived: sum of 3 quarters · filed 2026-05-13 | -$126.63M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$30.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$63.90M derived: sum of 2 quarters · filed 2026-03-12 | -$96.75M derived: sum of 3 quarters · filed 2026-03-12 | -$127.61M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$33.15M 10-Q · filed 2025-11-05 | -$66.00M derived: sum of 2 quarters · filed 2025-11-05 | -$96.87M 10-Q · filed 2025-11-05 | -$128.44M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$32.85M 10-Q · filed 2025-08-07 | -$63.72M 10-Q · filed 2025-08-07 | -$95.29M derived: sum of 3 quarters · filed 2025-08-07 | -$147.55M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$30.87M 10-Q · filed 2025-05-06 | -$62.44M derived: sum of 2 quarters · filed 2025-05-06 | -$114.70M derived: sum of 3 quarters · filed 2025-05-06 | -$149.59M derived: sum of 4 quarters · filed 2025-05-06 | ||||
| 2023-12-31 | -$31.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$83.83M derived: sum of 2 quarters · filed 2025-03-06 | -$118.72M derived: sum of 3 quarters · filed 2025-03-06 | -$152.04M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$52.26M 10-Q · filed 2024-11-06 | -$87.15M derived: sum of 2 quarters · filed 2024-11-06 | -$120.47M 10-Q · filed 2024-11-06 | -$152.04M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | -$34.89M 10-Q · filed 2024-08-13 | -$68.21M 10-Q · filed 2024-08-13 | -$99.78M derived: sum of 3 quarters · filed 2024-08-13 | -$122.76M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$33.32M 10-Q · filed 2024-05-14 | -$64.89M derived: sum of 2 quarters · filed 2024-05-14 | -$87.87M derived: sum of 3 quarters · filed 2024-05-14 | -$110.58M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$31.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$54.55M derived: sum of 2 quarters · filed 2024-03-19 | -$77.26M derived: sum of 3 quarters · filed 2024-03-19 | -$72.55M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | -$22.98M 10-Q · filed 2023-11-08 | -$45.69M derived: sum of 2 quarters · filed 2023-11-08 | -$40.99M 10-Q · filed 2023-11-08 | -$56.53M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$22.71M 10-Q · filed 2023-08-09 | -$18.00M 10-Q · filed 2023-08-09 | -$33.54M derived: sum of 3 quarters · filed 2023-08-09 | -$47.25M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $4.71M 10-Q · filed 2023-05-09 | -$10.84M derived: sum of 2 quarters · filed 2023-05-09 | -$24.55M derived: sum of 3 quarters · filed 2023-05-09 | -$35.37M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | -$15.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$29.25M derived: sum of 2 quarters · filed 2023-03-15 | -$40.08M derived: sum of 3 quarters · filed 2023-03-15 | -$61.43M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$13.71M 10-Q · filed 2022-11-08 | -$24.54M derived: sum of 2 quarters · filed 2022-11-08 | -$45.89M 10-Q · filed 2022-11-08 | -$55.24M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$10.83M 10-Q · filed 2022-08-10 | -$32.18M 10-Q · filed 2022-08-10 | -$41.53M derived: sum of 3 quarters · filed 2022-08-10 | -$55.19M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$21.35M 10-Q · filed 2022-05-12 | -$30.70M derived: sum of 2 quarters · filed 2022-05-12 | -$44.36M derived: sum of 3 quarters · filed 2022-05-12 | -$52.99M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$9.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$23.00M derived: sum of 2 quarters · filed 2022-03-15 | -$31.63M derived: sum of 3 quarters · filed 2022-03-15 | -$39.19M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$13.65M 10-Q · filed 2021-11-10 | -$22.29M derived: sum of 2 quarters · filed 2021-11-10 | -$29.84M 10-Q · filed 2021-11-10 | -$59.28M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$8.63M 10-Q · filed 2021-08-12 | -$5.65M 10-Q · filed 2020-07-30 | -$16.19M 10-Q · filed 2021-08-12 | -$13.03M 10-Q · filed 2020-07-30 | -$45.62M derived: sum of 3 quarters · filed 2021-08-12 | -$60.85M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$7.56M 10-Q · filed 2021-05-17 | -$7.38M 10-Q · filed 2020-05-07 | -$36.99M derived: sum of 2 quarters · filed 2021-05-17 | -$52.22M derived: sum of 3 quarters · filed 2021-05-17 | -$71.39M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | -$29.44M 10-K · filed 2020-03-12 | -$44.66M derived: sum of 2 quarters · filed 2020-11-05 | -$63.83M derived: sum of 3 quarters · filed 2020-11-05 | -$31.39M 10-K · filed 2021-03-12 | -$85.46M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | -$15.22M 10-Q · filed 2020-11-05 | -$25.16M 10-Q · filed 2019-11-05 | -$34.39M derived: sum of 2 quarters · filed 2020-11-05 | -$24.21M 10-Q · filed 2020-11-05 | -$56.02M 10-Q · filed 2019-11-05 | -$52.45M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | -$19.17M 10-Q · filed 2020-07-30 | -$30.86M 10-Q · filed 2020-07-30 | -$37.22M derived: sum of 3 quarters · filed 2020-07-30 | -$46.25M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2019-03-31 | -$11.69M 10-Q · filed 2020-05-07 | -$18.05M derived: sum of 2 quarters · filed 2020-05-07 | -$27.08M derived: sum of 3 quarters · filed 2020-05-07 | -$41.20M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$6.36M 10-K · filed 2020-03-12 | -$15.39M derived: sum of 2 quarters · filed 2020-03-12 | -$29.50M derived: sum of 3 quarters · filed 2020-03-12 | -$14.96M 10-K · filed 2021-03-12 | -$39.70M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | -$9.03M 10-K · filed 2020-03-12 | -$23.14M derived: sum of 2 quarters · filed 2020-03-12 | -$33.34M 10-Q · filed 2019-11-05 | -$40.87M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | -$14.11M 10-K · filed 2020-03-12 | -$24.31M 10-Q · filed 2019-08-14 | -$31.84M derived: sum of 3 quarters · filed 2020-03-12 | -$35.78M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | -$10.20M 10-K · filed 2020-03-12 | -$17.72M derived: sum of 2 quarters · filed 2020-03-12 | -$21.67M derived: sum of 3 quarters · filed 2020-03-12 | -$25.73M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | -$7.52M 10-K · filed 2019-03-18 | -$11.47M derived: sum of 2 quarters · filed 2019-03-18 | -$15.53M derived: sum of 3 quarters · filed 2019-03-18 | -$18.88M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | -$3.94M 10-K · filed 2019-03-18 | -$8.00M derived: sum of 2 quarters · filed 2019-03-18 | -$11.36M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | -$4.06M 10-K · filed 2019-03-18 | -$7.41M 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | -$3.36M 10-K · filed 2019-03-18 | |||||||
| 2016-12-31 | -$1.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |